Corcept Therapeutics (CORT) reported Q4 net income late Wednesday of $0.26 per diluted share, down from $0.28 a year earlier.
Revenue for the quarter ended Dec. 31 was $181.9 million, up from $135.4 million a year earlier.
Analysts surveyed by FactSet expected $198.7 million.
The company said it expects 2025 revenue of $900 million to $950 million. Analysts expected $841.6 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.